Delivery of intraocular triamcinolone acetonide in the treatment of macular edema

Aaron Pickrell; Alon Harris; Sandra Ngo; Annahita Amireskandari; Erin Stewart; Brent Siesky

doi:10.3390/pharmaceutics4010230

Delivery of intraocular triamcinolone acetonide in the treatment of macular edema

Aaron Pickrell
, Alon Harris
, Sandra Ngo
, Annahita Amireskandari
, Erin Stewart
, Brent Siesky

Research output: Contribution to journal › Review article › peer-review

5 Scopus citations

Abstract

Macular edema (ME) is one of the eventual outcomes of various intraocular and systemic pathologies. The pathogenesis for ME is not yet entirely understood; however, some of the common risk factors for its development have been identified. While this investigation will not discuss the numerous etiologies of ME in detail, it appraises the two most widely studied delivery modalities of intraocular corticosteroids in the treatment of ME-intravitreal injection (IVI) and sub-Tenon's infusion (STI). A thorough review of the medical literature was conducted to identify the efficacy and safety of IVI and STI, specifically for the administration of triamcinolone acetonide (TA), in the setting of ME in an attempt to elucidate a preferred steroid delivery modality for treatment of ME.

Original language	English
Pages (from-to)	230-242
Number of pages	13
Journal	Pharmaceutics
Volume	4
Issue number	1
DOIs	https://doi.org/10.3390/pharmaceutics4010230
State	Published - Mar 2012
Externally published	Yes

Keywords

Corticosteroids
Intravitreal injection
Macular edema
Sub-tenon's injection
Triamcinolone

Access to Document

10.3390/pharmaceutics4010230

Cite this

@article{409d609ae5d94ec6b168d0e5f90e9558,

title = "Delivery of intraocular triamcinolone acetonide in the treatment of macular edema",

abstract = "Macular edema (ME) is one of the eventual outcomes of various intraocular and systemic pathologies. The pathogenesis for ME is not yet entirely understood; however, some of the common risk factors for its development have been identified. While this investigation will not discuss the numerous etiologies of ME in detail, it appraises the two most widely studied delivery modalities of intraocular corticosteroids in the treatment of ME-intravitreal injection (IVI) and sub-Tenon's infusion (STI). A thorough review of the medical literature was conducted to identify the efficacy and safety of IVI and STI, specifically for the administration of triamcinolone acetonide (TA), in the setting of ME in an attempt to elucidate a preferred steroid delivery modality for treatment of ME.",

keywords = "Corticosteroids, Intravitreal injection, Macular edema, Sub-tenon's injection, Triamcinolone",

author = "Aaron Pickrell and Alon Harris and Sandra Ngo and Annahita Amireskandari and Erin Stewart and Brent Siesky",

year = "2012",

month = mar,

doi = "10.3390/pharmaceutics4010230",

language = "English",

volume = "4",

pages = "230--242",

journal = "Pharmaceutics",

issn = "1999-4923",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "1",

}

TY - JOUR

T1 - Delivery of intraocular triamcinolone acetonide in the treatment of macular edema

AU - Pickrell, Aaron

AU - Harris, Alon

AU - Ngo, Sandra

AU - Amireskandari, Annahita

AU - Stewart, Erin

AU - Siesky, Brent

PY - 2012/3

Y1 - 2012/3

N2 - Macular edema (ME) is one of the eventual outcomes of various intraocular and systemic pathologies. The pathogenesis for ME is not yet entirely understood; however, some of the common risk factors for its development have been identified. While this investigation will not discuss the numerous etiologies of ME in detail, it appraises the two most widely studied delivery modalities of intraocular corticosteroids in the treatment of ME-intravitreal injection (IVI) and sub-Tenon's infusion (STI). A thorough review of the medical literature was conducted to identify the efficacy and safety of IVI and STI, specifically for the administration of triamcinolone acetonide (TA), in the setting of ME in an attempt to elucidate a preferred steroid delivery modality for treatment of ME.

AB - Macular edema (ME) is one of the eventual outcomes of various intraocular and systemic pathologies. The pathogenesis for ME is not yet entirely understood; however, some of the common risk factors for its development have been identified. While this investigation will not discuss the numerous etiologies of ME in detail, it appraises the two most widely studied delivery modalities of intraocular corticosteroids in the treatment of ME-intravitreal injection (IVI) and sub-Tenon's infusion (STI). A thorough review of the medical literature was conducted to identify the efficacy and safety of IVI and STI, specifically for the administration of triamcinolone acetonide (TA), in the setting of ME in an attempt to elucidate a preferred steroid delivery modality for treatment of ME.

KW - Corticosteroids

KW - Intravitreal injection

KW - Macular edema

KW - Sub-tenon's injection

KW - Triamcinolone

UR - https://www.scopus.com/pages/publications/84858806622

U2 - 10.3390/pharmaceutics4010230

DO - 10.3390/pharmaceutics4010230

M3 - Review article

AN - SCOPUS:84858806622

SN - 1999-4923

VL - 4

SP - 230

EP - 242

JO - Pharmaceutics

JF - Pharmaceutics

IS - 1

ER -

Delivery of intraocular triamcinolone acetonide in the treatment of macular edema

Abstract

Keywords

Access to Document

Fingerprint

Cite this